Clin Osteol 2010; 15(4): 144-147

Potential new and less frequent indications of cinacalcetReview articles

F. ©vára

Throughout six years of the clinical use of cinacalcet, numerous articles have been published, describing cinacalcet therapy in situati­ ons outside indications stated in the summary of product characteristics (SPC). Not only in the Czech Republic, such use of a drug is possible. However, it should be supported by either sufficient literature evidence and/or current scientific knowledge. In such cases, the physician or health care facility take full responsibility for potential adverse effects of the drug. In the case of cinacalcet from the group of calcimimetics, the most common indications outside the approved SPC are secondary hyperparathyroidism in patients with stage 3 or 4 kidney disease, calciphylaxis of soft tissues and other extraosseous calcifications and the use cinacalcet in patients after kidney transplantation.

Keywords: parathormone, summary ofproduct characteristics (SPC), hyperparathyroidism, calciphylaxis

Published: December 11, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©vára F. Potential new and less frequent indications of cinacalcet. Osteologický bulletin. 2010;15(4):144-147.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal and pathophysiology: a review. Crit Rev Clin Lab Sci 2005;42:35-70. Go to original source...
    2. Brown EM. The Calcium sensing receptor: Physiology and pathop CaR-based therapeutics. Sub-Cellular Biochemistry 2007; 139-167. Go to original source...
    3. Brown EM, Hebert SC. A cloned extracellular Ca(2+)-sensing receptor: molecu­ lar mediator of the acti Kidney Int 1996;49:1042. Go to original source...
    4. Cheng I, Klingensmith ME, Chattopadhyay N et al. Identification and l on of the extracellular calcium-sensing receptor in human breast. J Clin Endocrinol Metab 1998;83:703. Go to original source...
    5. Ray JM, Squires PE, Curtis SB et al. Expression of the calcium-sensing rece on human antral gastrin cells in culture. J Clin Invest 1997;99:2328. Go to original source...
    6. Kameda Y, Mano H, Yamada Y et al. Calcium-sensing receptor in mature osteo­ clasts, which are bone resorbing cells. Biochem Biophys Res Commun 1998; 245:419. Go to original source...
    7. Hebert SC, Cheng S, Geibel J. Functions and roles of the extracellu sing receptor in the gastrointestinal tract. Cell Calcium 2004;35:239. Go to original source...
    8. Hebert SC. Extracellular calcium-sensing receptor: Implications for calci magnesium handling in the kidney. Kidney Int 1996;50:2129-2135. Go to original source...
    9. Sulková S a kol. Renální osteopatie. 1. vydání, Maxdorf, Praha 2007.
    10. Brown EM. Four parameter model of the sigmoidal relationship between PTH release and extracellular in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983;56:572. Go to original source...
    11. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of c nic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089-2100. Go to original source...
    12. Messa P, Macario F, Yaqoob M et al. The OPTIMA study: assessing a new cina­ calcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroi­ dism. Clin J Am Soc Nephrol 2008;3:36 45. Go to original source...
    13. Koenig KG, Lindberg JS, Zerwekh JE et al. Free and total 1,2 D levels in subjects with renal disease. Kidney Int 1992;41:161. Go to original source...
    14. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disea the study to evaluate early kidney disease. Kidney Int 2007;71:31. Go to original source...
    15. LaClair RE, Hellman RN, Karp SL et al. Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. Am J K Dis 2005;45:1026. Go to original source...
    16. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabo­ lism and disease treatment goals with cinacalcet HCL. Kidney Int 2005; 67:760. Go to original source...
    17. Charytan C, Coburn JW, Chonchol M et al. Cinacalcet hydrochloride is an effec­ tive treatment for secondary hyperparathyroid ving dialysis. Am J Kidney Dis 2005;46:58-67. Go to original source...
    18. Coyne DW. Cinacalcet should not be used to treat secondary hyperparathy in stage 3-4 chronic kidney disease. Nat Clin Pract Nephrol 2008;4:364-536. Go to original source...
    19. Chonchol M, Locatelli F, Abbound HE et al. A randomized, double-blind, place­ bo controlled study to assess the efficacy and safety of cinacalcet HCL pants with CKD not receiving dialysis. Am J Kidney Dis 2009;53:197-207. Go to original source...
    20. Esposito L, Rostaing L, Gennero I, Mehrenberger M, Durand D, Kamar N. Hypercalciuria induced by a high dose of cinacalcet in a renal-transplant re pient. Clin Nephrol 2007;68:245-248. Go to original source...
    21. Borchhardt KA, Heinzl H, Mayerwoger E, Horl WH, Haas M, Sunder-Plassmann G. Cinacalcet increases calcium excretion in hypercalcemic hyperparathy­ roidism after kidney transplantation. Transplantation 2008;86:919-924. Go to original source...
    22. Kalantar-Zadeh K, Kovesdy CP. Is It Worth Correcting Hyperparathyroidism if Hyperphosphatemia and Hypocalcemia Worsen? A Cinacalcet Story. Am J Kidney Dis 2009;53:183-188. Go to original source...
    23. De Francisco A, Pinera C, Palomar R. Cinacalcet should be used to trea ry hyperparathyroidism in stage 3-4 chronic kidney disease. Nat Clin Pract Nephrol 2008;4:366-367. Go to original source...
    24. Selye H, Gabbiani G, Strebel R. Sensitization to calciphylaxis by endogenou rathyroid hormone. Endocrinology 1962;71:554-560. Go to original source...
    25. Gipstein RM, Coburn JW, Adams DA, Lee DB, Parsa KR, Sellers A, Suki WN, Massry SG. Calcipylaxis in man: a syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med 1976;136:1273-1280. Go to original source...
    26. Angelis M, Wong L, Myers S, Wong L. Calciphylaxis in patiens on haemodialy­ sis: a prevalent study. Surgery 1997;122:1083. Go to original source...
    27. Llach F. Calcific uremic arteriolopathy (calciphylaxis): an evolving entit J Kidney Dis 1998 Sep;32(3):514-518. Go to original source...
    28. Essary LR, Wick MR. Cutaneous calciphylaxis. An underrecognized clinicopathologic entity. Am J Clin Pathol 2000;113:280-288. Go to original source...
    29. Robinson RM. Cinacalcet for treatment of calciphylaxis. Arch Dermatol 2007; 143. Go to original source...
    30. Janigan DT, Hirsch DJ, Klassen GA, MacDonald AS. Calcified subcutaneous ar­ terioles with infarcts of the subcutis an failure. Am J Kidney Dis 2000;35:588-594. Go to original source...
    31. Mazhar AR, Johnson RJ, Gillen D et al. Risk factors and mortality calciphylaxis in end-stage renal disease. Kidney Int 2001;60:324-329. Go to original source...
    32. Wenig RH, Sewell LD, Davis MD et al. Calciphylaxis: natural history, risk f analysis, and outcome. Am J Acad Dermatol 2007;56:569-579. Go to original source...
    33. Rogers NM, Teubner DJO, Coates TH. Calcific uremic arteriolopathy: advances in pathogenesis and treatment. Semin Dial 2007;20:150-157. Go to original source...
    34. Weenig RH. Pathogenesis of calciphylaxis: Hans Selye to nuclear factor k-B. J Am Acad Dermatol 2008;58:458^71. Go to original source...
    35. Rostaing L, el Feki S, Delisle MB. Calciphylaxis in chronic hemodialisi with protein S deficiency. Am J Nephrol 1995;15:524-527. Go to original source...
    36. Girotto JA, Harmon JW, Retner LE, Nicol TL, Wong L, Chen H. Para­ thyreoidectomy promotes wound healing and prolongs survival in patiens with calciphylaxis from secondary hyperparathyroidism. Surgery 2001;130:645-651. Go to original source...
    37. Sharma A et al. Cinacalcet as an adjunct in the succes laxis. British Journal of Dermatology 2006; 155:1293-1307. Go to original source...
    38. Velasco N et al. Successful treatment of calciphylaxis with cinacalcet - an alt native to parathyroidectomy? Nephrol Dial Transplant 2006;21:1999-2004. Go to original source...
    39. Bleyer AJ, White WL, Choi MJ. Calcific small vessel ischemic disease (calciphy­ laxis) in dialysis patients [editorial]. Int J Artif Organs 2000;23:351-357. Go to original source...
    40. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recepient. Am J Transplant 2009; 9 (Suppl 3): S1-S168. Go to original source...
    41. Bergua C, Torregrosa JV, Fuster D, Gutiérrez-Dalmau A, Oppenheimer F, Campistol JM. Effect of Cinacalcet on Hypercalcemia and Bone Mineral Density in Renal Transplant Patients With Secondary Hyperparathyroidism. Transplan­ tation 2008;86:413 417 Go to original source...
    42. Lee PP, Schiffmann L, Offermann G, Beige J. Effects ofparathyroidectomy on re­ nal allograft survival. Kidney Blood Press Res 2004;27:191-196. Go to original source...
    43. Leca N, Laftavi M, Gundroo A et al. Early and Severe Hyperparathyroidism Associated with Hypercalcemia After Renal Transplant Treated with Cinacalcet. Am J Transplant 2006;6:2391-2395. Go to original source...
    44. Serra AL, Schwarz AA, Wick FH, Marti HP, Wuthrich RP. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hy­ perparathyroidism. Nephrol Dial Transplant 2005;20:1315-1319. Go to original source...
    45. Kruse A, Eisenberger U, Frey F, Mohaupt M. Effect of cinacalcet cessation in re­ nal transplant recipients with persistent hyperparathyroidism. Nephrol plant 2007;22:2362-2365. Go to original source...
    46. Exposito L, Rostaing L, Gennero I, Mehrenberger M, Durand D, Kamar N. Hypercalciuria induced by a high pient. Clin Nephrol 2007;68:245-248. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.